Catastrophic Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report.
- Author:
JinShik SHIN
1
;
Kwang Nam KIM
Author Information
- Publication Type:Case Report
- Keywords: Antiphospholipid syndrome; Systemic lupus erythematosus; Rituximab
- MeSH: Adolescent; Adrenal Cortex Hormones; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome*; Clinical Protocols; Female; Follow-Up Studies; Humans; Immunoglobulins; Korea; Lupus Erythematosus, Systemic*; Mortality; Plasmapheresis; Rituximab*; Thrombosis
- From:Journal of Rheumatic Diseases 2019;26(1):74-78
- CountryRepublic of Korea
- Language:English
- Abstract: The catastrophic variant of antiphospholipid syndrome (APS) is a very rare and life-threatening condition of APS. This condition is characterized by thrombosis in multiple organs within a short period of time in the presence of positive antiphospholipid antibodies (aPL). Over the past few decades, considerable progress has been made in the treatment of patients with catastrophic APS; however, the mortality rate still remains very high. Although some cases of rituximab treatment in patients with catastrophic APS have been reported, there is no clear treatment protocol. A 14-year-old girl with systemic lupus erythematosus was diagnosed with catastrophic APS. She received several medications: corticosteroids, intravenous immunoglobulin, and plasmapheresis with anticoagulants. Unfortunately, she did not improve, and rituximab was started with four courses. After the rituximab treatment, she did not experience further thrombotic events during the follow up. This paper reports a pediatric case of catastrophic APS treated successfully with rituximab in Korea.
